Overview

HyQvia in Multifocal Motor Neuropathy

Status:
Unknown status

Trial end date:
2018-01-01

Target enrollment:

Participant gender:

Summary

Subcutaneous immunoglobulin (SCIG) and recombinant human hyaluronidase (rHuPH20) will be tested in patient witch MMN and currently under maintenance treatment with IVIG for safety, tolerability and efficacy.

Phase:

N/A

Details

Lead Sponsor:

UMC Utrecht

Treatments:

Antibodies
Immunoglobulins